TABLE 2.
Overall | Group L | Group S | p‐value | |
---|---|---|---|---|
Size, mm (median, range) | 24 (3–170) | 23 (3–160) | 25 (4–170) | 0.310 |
Macroscopic type | 0.760 | |||
Type 0‐I, 0‐IIa, 0‐IIb | 29/377 (7.69%) | 8/84 (9.52%) | 21/293 (7.17%) | |
Type 0‐IIc, 0‐IIa+IIc | 282/377 (74.8%) | 61/84 (72.6%) | 221/293 (75.4%) | |
Type 1, 2, 3, 4, 5 | 66/377 (17.5%) | 15/84 (17.9%) | 51/293 (17.4%) | |
Location | 0.713 | |||
Upper | 120/377 (31.8%) | 28/84 (33.3%) | 92/293 (31.4%) | |
Middle | 140/377 (37.1%) | 33/84 (39.3%) | 107/293 (36.5%) | |
Lower | 117/377 (31.0%) | 23/84 (27.4%) | 94/293 (32.1%) | |
Invasive depth | 0.256 | |||
SM1 | 137/377 (36.3%) | 25/84 (29.8%) | 112/293 (38.2%) | |
SM2 | 149/377 (39.5%) | 34/84 (40.5%) | 115/293 (39.2%) | |
MP or deeper | 91/377 (24.1%) | 25/84 (29.8%) | 66/293 (22.5%) | |
Histological type | 0.023 | |||
Pure differentiated | 169/377 (44.8%) | 29/84 (34.5%) | 140/293 (47.8%) | |
Differentiated‐predominant mixed | 110/377 (29.2%) | 24/84 (28.6%) | 86/293 (29.4%) | |
Undifferentiated | 98/377 (26.0%) | 31/84 (36.9%) | 67/293 (22.9%) | |
Lymphovascular invasion | 186/366 (50.8%) | 42/78 (53.8%) | 144/288 (50.0%) | 0.700 |
Lymph node metastasis | 68/339 (20.1%) | 17/75 (22.7%) | 51/264 (19.3%) | 0.628 |
Distant metastasis | 9/339 (2.65%) | 5/75 (6.67%) | 4/264 (1.51%) | 0.031 |
Pathological stage | 0.060 | |||
IA | 227/339 (67.0%) | 42/75 (56.0%) | 185/264 (70.1%) | |
IB | 44/339 (13.0%) | 14/75 (18.7%) | 30/264 (11.4%) | |
IIA | 17/339 (5.01%) | 4/75 (5.33%) | 13/264 (4.92%) | |
IIB | 13/339 (3.83%) | 4/75 (5.33%) | 9/264 (3.41%) | |
IIIA or IIB or IIIC | 29/339 (8.55%) | 6/75 (8.00%) | 23/264 (8.71%) | |
IV | 9/339 (2.65%) | 5/75 (6.67%) | 4/264 (1.52%) | |
Endoscopic mucosal atrophy† | 0.608 | |||
Mild, C‐1, 2 | 32/377 (8.49%) | 9/84 (10.7%) | 23/293 (7.84%) | |
Moderate, C‐3, O‐1 | 157/377 (41.6%) | 32/84 (38.1%) | 125/293 (42.7%) | |
Severe, O‐2, 3 | 188/377 (49.9%) | 43/84 (51.2%) | 145/293 (49.5%) |
†Kimura‐Takemoto classification.
Abbreviations: C, closed; O, open.
Group L, Group of invasive gastric cancers diagnosed ≥10 years after H. pylori eradication; Group S, Group of invasive gastric cancers diagnosed <10 years after H. pylori eradication; SM1, submucosal invasion <0.5mm; SM2, submucosal invasion ≥0.5mm; MP, muscularis propria.